A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes
- PMID: 20051220
- DOI: 10.4088/JCP.08m04902pur
A comparison of the efficacy of medications for adult attention-deficit/hyperactivity disorder using meta-analysis of effect sizes
Abstract
Objectives: Medications used to treat attention-deficit/hyperactivity disorder (ADHD) in adults have been well researched, but comparisons among drugs are hindered by the absence of direct comparative trials. Our objectives were to (1) estimate the effect size of the medications used to treat adult ADHD, (2) determine if differences in the designs of studies confound comparisons of medication efficacy, (3) quantify the evidence for differences in effect sizes among medications, and (4) see if features of study design influence estimates of efficacy.
Data sources: The following search engines were used: PubMed, Ovid, ERIC, CINAHL, MEDLINE, PREMEDLINE, the Cochrane database, e-psyche, and Social Sciences Abstracts. Presentations from the American Psychiatric Association and American Academy of Child and Adolescent Psychiatry meetings were reviewed.
Study selection: A literature search was conducted to identify double-blind, placebo-controlled studies of ADHD in adults published in English after 1979. Only trials that used DSM-III, -III-R, or -IV ADHD criteria and followed subjects for > or = 2 weeks were selected.
Data extraction: Meta-analysis regression assessed the influence of medication type and study design features on medication effects.
Results: Nineteen trials met criteria and were included in this meta-analysis. These trials studied 13 drugs using 18 different outcome measures of hyperactive, inattentive, or impulsive behavior. After trials were stratified on the class of drug studied (short-acting stimulant vs long-acting stimulant vs nonstimulant), significant differences in effect size were observed between stimulant and nonstimulant medications (P = .006 and P = .0001, respectively, for short- and long-acting stimulants vs nonstimulants), but the effect for short-acting stimulants was not significant after correcting for study design features. The effect sizes for each drug class were similar in magnitude to what we previously reported for medication treatment studies of children with ADHD. We found significant heterogeneity of effect sizes for short-acting stimulants (P < .001) but not for other medication groups.
Conclusions: Although both stimulant and nonstimulant medications are effective for treating ADHD in adults, stimulant medications show greater efficacy for the short durations of treatment characteristic of placebo-controlled studies. We found no significant differences between short- and long-acting stimulant medications. Study design features vary widely among studies and can confound indirect comparisons unless addressed statistically as we have done in this study.
2010 Physicians Postgraduate Press, Inc.
Similar articles
-
Pharmacological treatment patterns among patients with attention-deficit/hyperactivity disorder: retrospective claims-based analysis of a managed care population.Curr Med Res Opin. 2010 Apr;26(4):977-89. doi: 10.1185/03007991003673617. Curr Med Res Opin. 2010. PMID: 20178404
-
Efficacy and safety of mixed amphetamine salts extended release (Adderall XR) in the management of attention-deficit/hyperactivity disorder in adolescent patients: a 4-week, randomized, double-blind, placebo-controlled, parallel-group study.Clin Ther. 2006 Feb;28(2):266-79. doi: 10.1016/j.clinthera.2006.02.011. Clin Ther. 2006. PMID: 16678648 Clinical Trial.
-
Modafinil improves symptoms of attention-deficit/hyperactivity disorder across subtypes in children and adolescents.J Pediatr. 2008 Mar;152(3):394-9. doi: 10.1016/j.jpeds.2007.07.052. Epub 2007 Oct 24. J Pediatr. 2008. PMID: 18280848
-
Evolution of the treatment of attention-deficit/hyperactivity disorder in children: a review.Clin Ther. 2008 May;30(5):942-57. doi: 10.1016/j.clinthera.2008.05.006. Clin Ther. 2008. PMID: 18555941 Review.
-
Attention-deficit-hyperactivity disorder: an update.Pharmacotherapy. 2009 Jun;29(6):656-79. doi: 10.1592/phco.29.6.656. Pharmacotherapy. 2009. PMID: 19476419 Review.
Cited by
-
Why most biomedical findings echoed by newspapers turn out to be false: the case of attention deficit hyperactivity disorder.PLoS One. 2012;7(9):e44275. doi: 10.1371/journal.pone.0044275. Epub 2012 Sep 12. PLoS One. 2012. PMID: 22984483 Free PMC article.
-
ADHD, financial distress, and suicide in adulthood: A population study.Sci Adv. 2020 Sep 30;6(40):eaba1551. doi: 10.1126/sciadv.aba1551. Print 2020 Sep. Sci Adv. 2020. PMID: 32998893 Free PMC article.
-
Attention deficit hyperactivity disorder medications and bone mineral density of adults in the United States.Bone Rep. 2022 Apr 20;16:101570. doi: 10.1016/j.bonr.2022.101570. eCollection 2022 Jun. Bone Rep. 2022. PMID: 35519289 Free PMC article.
-
Adult attention-deficit/hyperactivity disorder treatment and cardiovascular implications.Curr Psychiatry Rep. 2011 Oct;13(5):357-63. doi: 10.1007/s11920-011-0213-3. Curr Psychiatry Rep. 2011. PMID: 21698412 Review.
-
Drug Treatment of Epilepsy Neuropsychiatric Comorbidities in Children.Paediatr Drugs. 2021 Jan;23(1):55-73. doi: 10.1007/s40272-020-00428-w. Epub 2020 Nov 24. Paediatr Drugs. 2021. PMID: 33230678 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Miscellaneous